Want to see APVO full AI Analyst Report?
APVO Stock Chart & Stats
$0.61
-$0.30(-5.81%)
At close: 4:00 PM EST
$0.61
-$0.30(-5.81%)
Day’s Range― - ―
52-Week Range$3.68 - $59.04
Previous CloseN/A
Volume25.11K
Average Volume (3M)11.64M
Market Cap
$5.47M
Enterprise Value-$5.57
Total Cash (Recent Filing)$14.53M
Total Debt (Recent Filing)$4.42M
Price to Earnings (P/E)―
Beta0.05
Next Earnings
Aug 06, 2026EPS Estimate
-6.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-357.16
Shares Outstanding1,246,105
10 Day Avg. Volume7,942,705
30 Day Avg. Volume11,635,265
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$21.00Price Target Upside3342.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-24.13
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Differentiated Clinical Data (AML)Robust Phase 1b results with high remission and clinical benefit rates materially increase the program's probability of advancement and partner interest. Orphan designation and deep MRD-negative responses support a sustainable clinical differentiation versus standard venetoclax+azacitidine in frontline AML, improving long-term commercialization and partnering prospects if later-stage results hold.
Strategic Radiopharma CollaborationThe Niowave collaboration structurally diversifies Aptevo into radiopharmaceuticals, granting access to scarce isotopes, reciprocal IP licensing, and aligned financial incentives via Niowave equity. This expands modality reach, reduces supply risk for alfa therapies, and creates shared development capacity that materially strengthens pipeline breadth and long-term partner-backed resources.
Non-dilutive Grant FundingA merit-based $1.5M grant provides non-dilutive capital targeted to IND-enabling work for APVO451 and validates the nectin-4 trispecific strategy. This funding extends program runway, lowers immediate financing needs for a prioritized asset, and helps preserve equity while advancing preclinical milestones that increase the program's licensing or partnership value.
Bears Say
High Cash Burn And Negative Cash FlowPersistent large operating losses and negative cash flow create a durable financing need; the company must repeatedly access capital or partnerships to fund R&D. That ongoing burn elevates dilution risk, constrains long-term program sequencing, and reduces flexibility to sustain multiple clinical programs without material external financing or milestone payments.
Limited Balance Sheet CushionWhile leverage is moderate, equity is small and returns are negative, leaving limited financial cushion against prolonged burn or trial delays. Volunteer capital may be available but terms could be dilutive; small equity and volatile shareholder base reduce negotiating leverage on partner deals and heighten execution risk over the medium term.
No Commercial Products; Partnership-Dependent RevenueAbsence of marketed products means sustainable revenue is contingent on lumpy milestone and collaboration payments. This structural reliance creates unpredictability for cash generation and margin sustainability, making long-term R&D planning and consistent funding more vulnerable to clinical setbacks or partner priorities shifting away.
Aptevo Therapeutics News
APVO FAQ
What was Aptevo Therapeutics Inc’s price range in the past 12 months?
Aptevo Therapeutics Inc lowest stock price was $3.68 and its highest was $59.04 in the past 12 months.
What is Aptevo Therapeutics Inc’s market cap?
Aptevo Therapeutics Inc’s market cap is $5.47M.
When is Aptevo Therapeutics Inc’s upcoming earnings report date?
Aptevo Therapeutics Inc’s upcoming earnings report date is Aug 06, 2026 which is in 12 days.
How were Aptevo Therapeutics Inc’s earnings last quarter?
Aptevo Therapeutics Inc released its earnings results on May 07, 2026. The company reported -$6.41 earnings per share for the quarter, missing the consensus estimate of -$5.6 by -$0.81.
Is Aptevo Therapeutics Inc overvalued?
According to Wall Street analysts Aptevo Therapeutics Inc’s price is currently Undervalued.
Does Aptevo Therapeutics Inc pay dividends?
Aptevo Therapeutics Inc does not currently pay dividends.
What is Aptevo Therapeutics Inc’s EPS estimate?
Aptevo Therapeutics Inc’s EPS estimate is -6.02.
How many shares outstanding does Aptevo Therapeutics Inc have?
Aptevo Therapeutics Inc has 1,246,105 shares outstanding.
What happened to Aptevo Therapeutics Inc’s price movement after its last earnings report?
Aptevo Therapeutics Inc reported an EPS of -$6.41 in its last earnings report, missing expectations of -$5.6. Following the earnings report the stock price went down -1.619%.
Which hedge fund is a major shareholder of Aptevo Therapeutics Inc?
Currently, no hedge funds are holding shares in APVO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aptevo Therapeutics Inc
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company primarily focused on pioneering immunotherapeutic agents for a variety of cancer treatments across the United States. Its foremost investigational drug, APVO436, is a bispecific antibody crafted to engage T-cells, which is currently undergoing a Phase 1b clinical study for acute myeloid leukemia and myelodysplastic syndromes. Beyond its lead asset, Aptevo's research pipeline encompasses several preclinical compounds. These include ALG.APV-527, an experimental bispecific ADAPTIR molecule designed to target both 4-1BB (CD137) and 5T4, a tumor-specific antigen prevalent in numerous cancer types. Another promising candidate is APVO603, a dual agonist bispecific antibody that targets both 4-1BB and OX40. The company is also advancing APVO442, a bispecific agent leveraging its ADAPTIR-FLEX platform technology to improve the precise delivery of drugs to prostate-specific membrane antigen (PSMA)-positive tumors for the treatment of prostate cancer. To further its development efforts for ALG.APV-527, Aptevo maintains a collaborative partnership and option agreement with Alligator Bioscience AB. Founded in 2016, Aptevo Therapeutics Inc. operates from its headquarters located in Seattle, Washington.
APVO Stock 12 Month Forecast
Average Price Target
$21.00
▲(3342.62% Upside)
Technical Analysis
Ownership Overview
1.09% Insiders
1.79% Mutual Funds
<0.01% Other Institutional Investors
96.10% Public Companies and
Individual Investors